Highlights Neurizon Therapeutics Limited

Stocks

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 11:22:33 10/07/2026 am IST			5-day change	1st Jan Change
0.0670 ^AUD	+3.08%		-4.29%	-21.18%

12/06	Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment	MT
27/05	Neurizon Therapeutics Limited Expands Regimen I of the Healey Als Platform Trial to 240 Participants	CI

Highlights

27/05	Neurizon Therapeutics Limited Expands Regimen I of the Healey Als Platform Trial to 240 Participants	CI
13/05	Neurizon Therapeutics receives ethics approval for Phase 1 Nuz-001 oral liquid formulation study	RE
13/05	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT
27/02	Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial	CI
25/02	Neurizon Therapeutics posts loss for half year attributable of A$5.5 million	RE
25/02	Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE
04/12	Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%	MT
26/11	Neurizon Therapeutics Limited Announces the Appointment of Justine Conway as Board Observer	CI
21/25/21	Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment	MT
06/25/06	Neurizon Therapeutics Limited Announces U.S. Food and Drug Administration Lifts Clinical Hold on Nuz-001	CI
06/25/06	FDA lifts clinical hold on Nuz-001	RE
06/25/06	Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001	RE
06/25/06	Neurizon Therapeutics Says US FDA Lifts Clinical Hold on Amyotrophic Lateral Sclerosis Drug Candidate	MT
26/25/26	Neurizon Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
26/25/26	Neurizon Therapeutics posts loss for year attributable a$16.6 million	RE
15/25/15	Neurizon Says US FDA Delays Decision on ALS Drug Application Clinical Hold; Shares Fall 6%	MT
25/25/25	Neurizon Therapeutics Submit Formal Response to US FDA for Investigational New Drug Application; Shares Up 19%	MT
10/25/10	Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	MT
02/25/02	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT
16/25/16	Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	CI
04/25/04	Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	MT
04/25/04	Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	CI